Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology

Behavioural Neurology

Volumn 2015, Issue , 2015, Pages

  Yu, Shaobin ^a   Zhu, Ling ^a   Shen, Qiang ^b   Bai, Xue ^a   Di, Xuhui ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Department of Neurology Hospitals OfThe Armed Police Forces in Hebei   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; DOPAMINE; DOPAMINE 3 RECEPTOR; GAMMA INTERFERON; METHAMPHETAMINE; MINOCYCLINE; PROTEIN P53; TRANSACTIVATOR PROTEIN; UBIQUITIN;

AUTOPHAGY; CELL SURVIVAL; CORPUS STRIATUM; DEACETYLATION; ENDOPLASMIC RETICULUM STRESS; EXCITOTOXICITY; GENE THERAPY; GLIOSIS; HIPPOCAMPUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROTUBULE; MOLECULAR PATHOLOGY; NERVE ENDING; NEUROTOXICITY; NITRATION; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; BRAIN; DRUG EFFECTS; ENDOPLASMIC RETICULUM; GENE EXPRESSION; METABOLISM; NEUROTOXICITY SYNDROMES;

ANIMALS; BRAIN; DOPAMINE; ENDOPLASMIC RETICULUM; GENE EXPRESSION; HUMANS; METHAMPHETAMINE; NEUROTOXICITY SYNDROMES;

EID: 84925637643     PISSN: 09534180     EISSN: 18758584     Source Type: Journal    
DOI: 10.1155/2015/103969     Document Type: Review

References (155)

1. W. J. Panenka, R. M. Procyshyn, T. Lecomte et al., "Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings," Drug and Alcohol Dependence, vol. 129, no. 3, pp. 167-179, 2013.
2. M. D. Anglin, C. Burke, B. Perrochet, E. Stamper, and S. Dawud-Noursi, "History of the methamphetamine problem," Journal of Psychoactive Drugs, vol. 32, no. 2, pp. 137-141, 2000.
3. S. J. Kish, "Pharmacologic mechanisms of crystal meth," CanadianMedical Association Journal, vol. 178, no. 13, pp. 1679-1682, 2008.
4. I. E. Cisneros and A. Ghorpade, "Methamphetamine and HIV- 1-induced neurotoxicity: role of trace amine associated receptor 1cAMPsignaling in astrocytes," Neuropharmacology, vol. 85, pp. 499-507, 2014.
5. N. D. Volkow, J. S. Fowler, G.-J. Wang et al., "Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications," PLoS ONE, vol. 5, no. 12, Article ID e15269, 2010.
6. J. F. Marshall and S. J. O'Dell, "Methamphetamine influences on brain and behavior: unsafe at any speed?" Trends in Neurosciences, vol. 35, no. 9, pp. 536-545, 2012.
7. J. L. Cadet, S. Jayanthi, and X. Deng, "Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis," The FASEB Journal, vol. 17, no. 13, pp. 1775-1788, 2003.
8. J. P. O'Callaghan, K. Sriram, and D. B. Miller, "Defining 'neuroinflammation': lessons from MPTP- and methamphetamineinduced neurotoxicity," Annals of the New York Academy of Sciences, vol. 1139, no. 10, pp. 318-330, 2008.
9. B. K. Yamamoto, A. Moszczynska, and G. A. Gudelsky, "Amphetamine toxicities: classical and emerging mechanisms," Annals of the New York Academy of Sciences, vol. 1187, pp. 101-121, 2010.
10. G. A. Ricaurte, A. O. Mechan, J. Yuan et al., "Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates," Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 1, pp. 91-98, 2005.
11. R. C. Callaghan, J. K. Cunningham, J. Sykes, and S. J. Kish, "Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use ofmethamphetamine or other amphetamine-type drugs," Drug and Alcohol Dependence, vol. 120, no. 1-3, pp. 35-40, 2012.
12. R. Potula, B. J. Hawkins, J. M. Cenna et al., "Methamphetamine causes mitrochondrial oxidative damage in human T lymphocytes leading to functional impairment," Journal of Immunology, vol. 185, no. 5, pp. 2867-2876, 2010.
13. L. E. Halpin, S. A. Collins, and B. K. Yamamoto, "Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine," Life Sciences, vol. 97, no. 1, pp. 37-44, 2014.
14. K.A. Mark, J. J. Soghomonian, and B.K. Yamamoto, "High-dose methamphetamine acutely-activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity," The Journal of Neuroscience, vol. 24, no. 50, pp. 11449-11456, 2004.
15. L. S. Seiden, D. L. Commins, G. Vosmer, K. Axt, and G. Marek, "Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections," Annals of the New York Academy of Sciences, vol. 537, pp. 161-172, 1988.
16. E. Floor and L. Meng, "Amphetamine releases dopamine from synaptic vesicles by dual mechanisms,"Neuroscience Letters, vol. 215, no. 1, pp. 53-56, 1996.
17. A.K. Bansal, C. F. MacTutus, A. Nath, W. Maragos, K. F. Hauser, and R. M. Booze, "Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum," Brain Research, vol. 879, no. 1-2, pp. 42-49, 2000.
18. G. Zauli, P. Secchiero, L. Rodella et al., "HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells," Journal of Biological Chemistry, vol. 275, no. 6, pp. 4159-4165, 2000.
19. W.A. Cass, M. E. Harned, L. E. Peters, A. Nath, and W. F. Maragos, "HIV-1 protein Tat potentiation of methamphetamineinduced decreases in evoked overflow of dopamine in the striatum of the rat," Brain Research, vol. 984, no. 1-2, pp. 133-142, 2003.
20. M. Yamato, W. Kudo, T. Shiba, K.-I. Yamada, T. Watanabe, and H. Utsumi, "Determination of reactive oxygen species associated with the degeneration of dopaminergic neurons during dopamine metabolism," Free Radical Research, vol. 44, no. 3, pp. 249-257, 2010.
21. T. Kita, I. Miyazaki, M. Asanuma, M. Takeshima, and G. C. Wagner, "Dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity," International Review of Neurobiology, vol. 88, no. 1, pp. 43-64, 2009.
22. I. Miyazaki and M. Asanuma, "Approaches to prevent dopamine quinone-induced neurotoxicity," Neurochemical Research, vol. 34, no. 4, pp. 698-706, 2009.
23. X. Li, H. Wang, P. Qiu, and H. Luo, "Proteomic profiling of proteins associated withmethamphetamine-induced neurotoxicity in different regions of rat brain," Neurochemistry International, vol. 52, no. 1-2, pp. 256-264, 2008.
24. F. Zhang, L. Chen, C. Liu et al., "Up-regulation of protein tyrosine nitration in methamphetamine-induced neurotoxicity through DDAH/ADMA/NOS pathway," Neurochemistry International, vol. 62, no. 8, pp. 1055-1064, 2013.
25. T. Pan, S. Kondo, W. Le, and J. Jankovic, "The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease," Brain, vol. 131, no. 8, pp. 1969-1978, 2008.
26. N. Mizushima, "Autophagy: process and function," Genes & Development, vol. 21, no. 22, pp. 2861-2873, 2007.
27. R. Castino, G. Lazzeri, P. Lenzi et al., "Suppression of autophagy precipitates neuronal cell death following low doses ofmethamphetamine," Journal of Neurochemistry, vol. 106, no. 3, pp. 1426-1439, 2008.
28. F. Fornai, P. Lenzi, L. Capobianco et al., "Involvement of dopamine receptors and β-arrestin in metamphetamineinduced inclusions formation in pc12 cells," Journal of Neurochemistry, vol. 105, no. 5, pp. 1939-1947, 2008.
29. L. Quan, T. Ishikawa, T. Michiue et al., "Ubiquitin-immunoreactive structures in the midbrain of methamphetamine abusers," Legal Medicine, vol. 7, no. 3, pp. 144-150, 2005.
30. J. F. Bowyer, P. Clausing, B. Gough, W. Slikkert Jr., and R. R. Holson, "Nitric oxide regulation of methamphetamine-induced dopamine release in caudate/putamen," Brain Research, vol. 699, no. 1, pp. 62-70, 1995.
31. J. L. Cadet and C. Brannock, "Free radicals and the pathobiology of brain dopamine systems," Neurochemistry International, vol. 32, no. 2, pp. 117-131, 1997.
32. S. Jayanthi, X. Deng, P.-A. H. Noailles, B. Ladenheim, and J. L. Cadet, "Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondriadependent death cascades,"TheFASEB Journal, vol. 18, no. 2, pp. 238-251, 2004.
33. S. Jayanthi, M. T. McCoy, G. Beauvais et al., "Methamphetamine induces dopamine D1 receptor-dependent endoplasmic reticulum stress-related molecular events in the rat striatum," PLoS ONE, vol. 4, no. 6, Article ID e6092, 2009.
34. D. Israeli, E. Tessler, Y. Haupt et al., "A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis,"TheEMBO Journal, vol. 16, no. 14, pp. 4384-4392, 1997.
35. Y. Higashi, M. Asanuma, I. Miyazaki et al., "The p53-activated gene, PAG608, requires a zinc finger domain for nuclear localization and oxidative stress-induced apoptosis," The Journal of Biological Chemistry, vol. 277, no. 44, pp. 42224-42232, 2002.
36. J. J. Miguel-Hidalgo, "The role of glial cells in drug abuse," Current Drug Abuse Reviews, vol. 2, no. 1, pp. 76-82, 2009.
37. B. Ladenheim, I. N. Krasnova, X. Deng et al., "Methamphetamine- induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6," Molecular Pharmacology, vol. 58, no. 6, pp. 1247-1256, 2000.
38. S. Jayanthi, X. Deng, B. Ladenheim et al., "Calcineurin/NFATinduced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 868-873, 2005.
39. Q. Yu, D. Zhang, M. Walston, J. Zhang, Y. Liu, and R. R. Watson, "Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice," International Immunopharmacology, vol. 2, no. 7, pp. 951-962, 2002.
40. T. Kita, K. Shimada, Y. Mastunari, G. C. Wagner, K. Kubo, and T. Nakashima, "Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice," Neuropharmacology, vol. 39, no. 3, pp. 399-406, 2000.
41. Y. Chen, R. Song, R.-F. Yang, N. Wu, and J. Li, "A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rat," European Journal of Pharmacology, vol. 743, no. 4, pp. 126-132, 2014.
42. S. Fernandes, S. Salta, J. Bravo, A. P. Silva, and T. Summavielle, "Acetyl-L-carnitine prevents methamphetamine-induced structural damage on endothelial cells via ILK-related MMP-9 activity," Molecular Neurobiology, 2014.
43. M. Colovic and S. Caccia, "Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat," Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 791, no. 1-2, pp. 337-343, 2003.
44. S. C. Fagan, D. J. Edwards, C. V. Borlongan et al., "Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection," Experimental Neurology, vol. 186, no. 2, pp. 248-251, 2004.
45. S. Zhu, I. G. Stavrovskaya, M. Drozda et al., "Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice," Nature, vol. 417, no. 6884, pp. 74-78, 2002.
46. M. Chen, V. O. Ona, M. Li et al., "Minocycline inhibits caspase- 1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease," Nature Medicine, vol. 6, no. 7, pp. 797-801, 2000.
47. X. Wang, S. Zhu, M. Drozda et al., "Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10483-10487, 2003.
48. H. Hozumi, M. Asanuma, I. Miyazaki et al., "Protective effects of interferon-γ against methamphetamine-induced neurotoxicity," Toxicology Letters, vol. 177, no. 2, pp. 123-129, 2008.
49. H. Y. Gou, D. Wen, C. L. Ma et al., "Protective effects of cholecystokinin-8 on methamphetamine-induced behavioral changes and dopaminergic neurodegeneration in mice," Behavioural Brain Research, vol. 283, no. 4, pp. 87-96, 2015.
50. Z. Yu, H. Luo, W. Fu, and M. P. Mattson, "The endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: Suppression of oxidative stress and stabilization of calcium homeostasis," Experimental Neurology, vol. 155, no. 2, pp. 302-314, 1999.
51. X. Yang, Y. Liu, C. Liu et al., "Inhibition of ROCK2 expression protects against methamphetamine-induced neurotoxicity in PC12 cells," Brain Research, vol. 1533, pp. 16-25, 2013.
52. S. L. Simon, C. P. Domier, T. Sim, K. Richardson, R. A. Rawson, and W. Ling, "Cognitive performance of current methamphetamine and cocaine abusers," Journal of Addictive Diseases, vol. 21, no. 1, pp. 61-74, 2002.
53. N. D. Volkow, L. Chang, G. J. Wang et al., "Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers," The American Journal of Psychiatry, vol. 158, no. 3, pp. 377-382, 2001.
54. L. Clark, T. W. Robbins, K. D. Ersche, and B. J. Sahakian, "Reflection impulsivity in current and former substance users," Biological Psychiatry, vol. 60, no. 5, pp. 515-522, 2006.
55. C.-E. Johanson, K.A. Frey, L. H. Lundahl et al., "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers," Psychopharmacology, vol. 185, no. 3, pp. 327-338, 2006.
56. R. C. Callaghan, J. K. Cunningham, G. Sajeev, and S. J. Kish, "Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders," MovementDisorders, vol. 25, no. 14, pp. 2333-2339, 2010.
57. S. J. Kish, P. S. Fitzmaurice, I. Boileau et al., "Brain serotonin transporter in human methamphetamine users," Psychopharmacology, vol. 202, no. 4, pp. 649-661, 2009.
58. N. D. Volkow, L. Chang, G.-J. Wang et al., "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence,"The Journal of Neuroscience, vol. 21, no. 23, pp. 9414-9418, 2001.
59. J.-H. Son, J. Kuhn, and K. A. Keefe, "Perseverative behavior in rats with methamphetamine-induced neurotoxicity," Neuropharmacology, vol. 67, pp. 95-103, 2013.
60. J. C. Tong, P. Fitzmaurice, Y. Furukawa et al., "Is brain gliosis a characteristic of chronic methamphetamine use in the human?" Neurobiology of Disease, vol. 67, no. 7, pp. 107-118, 2014.
61. M. V. Sofroniew and H. V. Vinters, "Astrocytes: biology and pathology," Acta Neuropathologica, vol. 119, no. 1, pp. 7-35, 2010.
62. W. J. Streit, "Microglial activation and neuroinflammation in Alzheimer's disease: a critical examination of recent history," Frontiers in Aging Neuroscience, vol. 2, article 22, Article ID Article 22, 2010.
63. D. Zhang, X. Hu, L. Qian, J. P. O'Callaghan, and J.-S. Hong, "Astrogliosis in CNS pathologies: is there a role for microglia?" Molecular Neurobiology, vol. 41, no. 2-3, pp. 232-241, 2010.
64. G. W. Kreutzberg, "Microglia: a sensor for pathological events in the CNS," Trends in Neurosciences, vol. 19, no. 8, pp. 312-318, 1996.
65. J. L. Ridet, S. K. Malhotra, A. Privat, and F. H. Gage, "Reactive astrocytes: cellular and molecular cues to biological function," Trends in Neurosciences, vol. 20, no. 12, pp. 570-577, 1997.
66. I. N. Krasnova, Z. Justinova, B. Ladenheim et al., "Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat," PLoS ONE, vol. 5, no. 1, Article ID e8790, 2010.
67. D. M. Thomas, P.D. Walker, J.A. Benjamins, T. J. Geddes, and D. M. Kuhn, "Methamphetamine neurotoxicity in dopamine nerve endings of the striatumis associated with microglial activation," Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 1, pp. 1-7, 2004.
68. J. Tong, P. Fitzmaurice, Y. Furukawa et al., "Is brain gliosis a characteristic of chronic methamphetamine use in the human?" Neurobiology of Disease, vol. 67, pp. 107-118, 2014.
69. T. Kadota and K. Kadota, "Neurotoxic morphological changes induced in the medial prefrontal cortex of rats behaviorally sensitized to methamphetamine," Archives of Histology and Cytology, vol. 67, no. 3, pp. 241-251, 2004.
70. J. L. Cadet, S. Jayanthi, and X. Deng, "Methamphetamineinduced neuronal apoptosis involves the activation of multiple death pathways. Review," Neurotoxicity Research, vol. 8, no. 3-4, pp. 199-206, 2005.
71. S. Jayanthi, B. Ladenheim, A. M. Andrews, and J. L. Cadet, "Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy)," Neuroscience, vol. 91, no. 4, pp. 1379-1387, 1999.
72. W. Jeng, A. Ramkissoon, T. Parman, and P.G. Wells, "Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration," The FASEB Journal, vol. 20, no. 6, pp. 638-650, 2006.
73. A. Ajjimaporn, S. Shavali, M. Ebadi, and P. Govitrapong, "Zinc rescues dopaminergic SK-N-SH cell lines from methamphetamine-induced toxicity," Brain Research Bulletin, vol. 77, no. 6, pp. 361-366, 2008.
74. S. Klongpanichapak, P. Phansuwan-Pujito, M. Ebadi, and P. Govitrapong, "Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity," Journal of Pineal Research, vol. 43, no. 1, pp. 65-73, 2007.
75. E. L. Riddle, A. E. Fleckenstein, and G. R. Hanson, "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity," The AAPS Journal, vol. 8, no. 2, pp. E413-E418, 2006.
76. K. Blackstone, J. E. Iudicello, E. E. Morgan et al., "Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use," Journal of Addiction Medicine, vol. 7, no. 4, pp. 255-263, 2013.
77. I. E. Cisneros and A. Ghorpade, "HIV-1, Methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS," Current HIV Research, vol. 10, no. 5, pp. 392-406, 2012.
78. R. J. Ellis, M. E. Childers, M. Cherner, D. Lazzaretto, S. Letendre, and I. Grant, "Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy," Journal of Infectious Diseases, vol. 188, no. 12, pp. 1820-1826, 2003.
79. S. J. Semple, T. L. Patterson, and I. Grant, "Motivations associated with methamphetamine use among HIV+ men who have sexwithmen," Journal of Substance Abuse Treatment, vol. 22, no. 3, pp. 149-156, 2002.
80. E. A. Kiyatkin and H. S. Sharma, "Environmental conditions modulate neurotoxic effects of psychomotor stimulant drugs of abuse," International Review of Neurobiology, vol. 102, no. 1, pp. 147-171, 2012.
81. G. Flora, Y. W. Lee, A. Nath, B. Hennig, W. Maragos, and M. Toborek, "Methamphetamine potentiates HIV-1 Tat proteinmediated activation of redox-sensitive pathways in discrete regions of the brain," Experimental Neurology, vol. 179, no. 1, pp. 60-70, 2003.
82. I. Miyazaki, M. Asanuma, F. J. Diaz-Corrales et al., "Methamphetamine- induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules," The FASEB Journal, vol. 20, no. 3, pp. 571-573, 2006.
83. D. M. Friend and K. A. Keefe, "A role for D1 dopamine receptors in striatal methamphetamine-induced neurotoxicity," Neuroscience Letters, vol. 555, pp. 243-247, 2013.
84. J. Yu, J. Wang, J. L. Cadet, and J. A. Angulo, "Histological evidence supporting a role for the striatal neurokinin-1 receptor in methamphetamine-induced neurotoxicity in the mouse brain," Brain Research, vol. 1007, no. 1-2, pp. 124-131, 2004.
85. J. P. Q. Zhu, W. Xu, and J. A. Angulo, "Methamphetamineinduced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice," Neuroscience, vol. 140, no. 2, pp. 607-622, 2006.
86. M. E. Reyland, "Protein kinase C isoforms: multi-functional regulators of cell life and death," Frontiers in Bioscience, vol. 14, no. 1, pp. 2386-2399, 2009.
87. D. Zhang, A. Kanthasamy, and V. Anantharam, "Effects of manganese on tyrosine hydroxylase (TH) activity and THphosphorylation in a dopaminergic neural cell line," Toxicology and Applied Pharmacology, vol. 254, no. 2, pp. 65-71, 2011.
88. M. Lin, P. Chandramani-Shivalingappa, H. Jin et al., "Methamphetamine- induced neurotoxicity linked to ubiquitin-proteasome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells," Neuroscience, vol. 210, pp. 308-332, 2012.
89. B. K. Yamamoto and M. G. Bankson, "Amphetamine neurotoxicity: cause and consequence of oxidative stress," Critical Reviews in Neurobiology, vol. 17, no. 2, pp. 87-117, 2005.
90. L. J. Ignarro, "Biosynthesis and metabolism of endotheliumderived nitric oxide," Annual Review of Pharmacology and Toxicology, vol. 30, pp. 535-560, 1990.
91. C. T. Tran, J. M. Leiper, and P. Vallance, "The DDAH-ADMANOS pathway," Therapeutic Drug Monitoring, vol. 27, no. 6, pp. 744-746, 2005.
92. J. A. de Andrade, J. P. Crow, L. Viera et al., "Protein nitration, metabolites of reactive nitrogen species, and inflammation in lung allografts,"TheAmerican Journal of Respiratory and Critical Care Medicine, vol. 161, no. 6, pp. 2035-2042, 2000.
93. A. H. K. Tsang and K. K. K. Chung, "Oxidative and nitrosative stress in Parkinson's disease," Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1792, no. 7, pp. 643-650, 2009.
94. A. Castegna, V. Thongboonkerd, J. B. Klein, B. Lynn, W. R. Markesberyl, and D. A. Butterfield, "Proteomic identification of nitrated proteins in Alzheimer's disease brain," Journal of Neurochemistry, vol. 85, no. 6, pp. 1394-1401, 2003.
95. R. A. Breckenridge, P. Kelly, M. Nandi, P. J. Vallance, T. J. Mohun, and J. Leiper, "A role for Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) in mammalian development," International Journal of Developmental Biology, vol. 54, no. 1, pp. 215-220, 2010.
96. D.-J. Jiang, S.-J. Jia, J. Yan, Z. Zhou, Q. Yuan, and Y.-J. Li, "Involvement of DDAH/ADMA/NOS pathway in nicotineinduced endothelial dysfunction," Biochemical and Biophysical Research Communications, vol. 349, no. 2, pp. 683-693, 2006.
97. O. Kitamura, I. Tokunaga, T. Gotohda, and S.-I. Kubo, "Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of humanmethamphetamine users," International Journal of Legal Medicine, vol. 121, no. 3, pp. 163-168, 2007.
98. O. Kitamura, T. Takeichi, E. L. Wang, I. Tokunaga, A. Ishigami, and S.-I. Kubo, "Microglial and astrocytic changes in the striatum of methamphetamine abusers," LegalMedicine, vol. 12, no. 2, pp. 57-62, 2010.
99. M. Schröder and R. J. Kaufman, "ER stress and the unfolded protein response," Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 569, no. 1-2, pp. 29-63, 2005.
100. K. D. McCullough, J. L. Martindale, L.-O. Klotz, T.-Y. Aw, and N. J. Holbrook, "Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bc12 and perturbing the cellular redox state," Molecular and Cellular Biology, vol. 21, no. 4, pp. 1249-1259, 2001.
101. H. Hirata and J. L. Cadet, "p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies," Journal of Neurochemistry, vol. 69, no. 2, pp. 780-790, 1997.
102. M. Asanuma, I. Miyazaki, Y. Higashi, J. L. Cadet, and N. Ogawa, "Methamphetamine-induced increase in striatal p53 DNAbinding activity is attenuated in Cu, Zn-superoxide dismutase transgenic mice," Neuroscience Letters, vol. 325, no. 3, pp. 191-194, 2002.
103. M. Asanuma, I. Miyazaki, Y. Higashi et al., "Suppression of p53-activated gene, PAG608, attenuates methamphetamineinduced neurotoxicity," Neuroscience Letters, vol. 414, no. 3, pp. 263-267, 2007.
104. M. Asanuma, T. Tsuji, I. Miyazaki, K. Miyoshi, and N. Ogawa, "Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug," Neuroscience Letters, vol. 352, no. 1, pp. 13-16, 2003.
105. M. J. LaVoie, J.P. Card, and T.G. Hastings, "Microglial activation precedes dopamine terminal pathology in methamphetamineinduced neurotoxicity," Experimental Neurology, vol. 187, no. 1, pp. 47-57, 2004.
106. L. Zhang, K. Kitaichi, Y. Fujimoto et al., "Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine," Progress in Neuro- Psychopharmacology and Biological Psychiatry, vol. 30, no. 8, pp. 1381-1393, 2006.
107. A. Nakajima, K. Yamada, T. Nagai et al., "Role of tumor necrosis factor-α in methamphetamine-induced drug dependence and neurotoxicity," Journal of Neuroscience, vol. 24, no. 9, pp. 2212-2225, 2004.
108. P. Sokoloff, J. Diaz, B. Le Foll et al., "The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders," CNS & Neurological Disorders - Drug Targets, vol. 5, no. 1, pp. 25-43, 2006.
109. B. Le Foll, G. Collo, E. A. Rabiner, I. Boileau, E. Merlo Pich, and P. Sokoloff, "Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings," Progress in Brain Research, vol. 211, no. 3, pp. 255-275, 2014.
110. J. Zhu, Y. Chen, N. Zhao et al., "Distinct roles of dopamine D3 receptors inmodulating methamphetamine-induced behavioral sensitization and ultrastructural plasticity in the shell of the nucleus accumbens," Journal of Neuroscience Research, vol. 90, no. 4, pp. 895-904, 2012.
111. A. E. Higley, S. W. Kiefer, X. Li, J. Gaál, Z.-X. Xi, and E. L. Gardner, "Dopamine D3 receptor antagonist SB- 277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats," European Journal of Pharmacology, vol. 659, no. 2-3, pp. 187-195, 2011.
112. A. C. Tziortzi, G. E. Searle, S. Tzimopoulou et al., "Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy," NeuroImage, vol. 54, no. 1, pp. 264-277, 2011.
113. M. G. Baladi, A. H. Newman, S. M. Nielsen, G. R. Hanson, and A. E. Fleckenstein, "Dopamine D3 receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia," European Journal of Pharmacology, vol. 732, pp. 105-110, 2014.
114. Y. Watanabe, T. Nakayama, D. Nagakubo et al., "Dopamine selectively induces migration and homing of naïve CD8+ T cells via dopamine receptor D3," Journal of Immunology, vol. 176, no. 2, pp. 848-856, 2006.
115. F. Mignini, D. Tomassoni, E. Traini, and F. Amenta, "Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen," Journal of Neuroimmunology, vol. 206, no. 1-2, pp. 5-13, 2009.
116. K. Z. Matalka, L. J. Attallah, N. A. Qinna, and T. Alhussainy, "Dopamine selectively modulates lipopolysaccharide-induced TNF-alpha, IFN-qamma and IL-10 within mice tissues," Neuroendocrinology Letters, vol. 32, no. 2, pp. 176-186, 2011.
117. N. A. Northrop and B. K. Yamamoto, "Persistent neuroinflammatory effects of serial exposure to stress and methamphetamine on the blood-brain barrier," Journal ofNeuroimmune Pharmacology, vol. 7, no. 4, pp. 951-968, 2012.
118. A. Urrutia, A. Rubio-Araiz, M. D. Gutierrez-Lopez et al., "A study on the effect of JNKinhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine," Neurobiology of Disease, vol. 50, no. 1, pp. 49-58, 2013.
119. S. M. Kousik, T. C. Napier, and P. M. Carvey, "The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation," Frontiers in Pharmacology, vol. 3, article 121, 2012.
120. M. Park, H.-J. Kim, B. Lim, A. Wylegala, and M. Toborek, "Methamphetamine-induced occludin endocytosis is mediated by the Arp2/3 complex-regulated actin rearrangement," Journal of Biological Chemistry, vol. 288, no. 46, pp. 33324-33334, 2013.
121. K. Sadoul, J. Wang, B. Diagouraga, and S. Khochbin, "The tale of protein lysine acetylation in the cytoplasm," Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 970382, 15 pages, 2011.
122. T. Martins, T. Burgoyne, B.-A. Kenny et al., "Methamphetamine- induced nitric oxide promotes vesicular transport in blood-brain barrier endothelial cells," Neuropharmacology, vol. 65, no. 2, pp. 74-82, 2013.
123. O. Omonijo, P. Wongprayoon, B. Ladenheim et al., "Differential effects of binge methamphetamine injections on the mRNA expression of histone deacetylases (HDACs) in the rat striatum," Neurotoxicology, vol. 45, no. 11, pp. 178-184, 2014.
124. M. Domercq and C. Matute, "Neuroprotection by tetracyclines," Trends in Pharmacological Sciences, vol. 25, no. 12, pp. 609-612, 2004.
125. V. W. Yong, J. Wells, F. Giuliani, S. Casha, C. Power, and L.M. Metz, "The promise of minocycline in neurology," The Lancet Neurology, vol. 3, no. 12, pp. 744-751, 2004.
126. M. Thomas and W. D. Le, "Minocycline: Neuroprotective mechanisms in Parkinson's disease," Current Pharmaceutical Design, vol. 10, no. 6, pp. 679-686, 2004.
127. Y. Du, Z. Ma, S. Lin et al., "Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 25, pp. 14669-14674, 2001.
128. D. J. Moore, "Parkin: a multifaceted ubiquitin ligase," Biochemical Society Transactions, vol. 34, no. 5, pp. 749-753, 2006.
129. H. Shimura, N. Hattori, S.-I. Kubo et al., "Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase," Nature Genetics, vol. 25, no. 3, pp. 302-305, 2000.
130. Y. Zhang, J. Gao, K. K. K. Chung, H. Huang, V. L. Dawson, and T. M. Dawson, "Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 24, pp. 13354-13359, 2000.
131. O. A. Buneeva and A. E. Medvedev, "Ubiquitin-protein ligase parkin and its role in the development of Parkinson's disease," Biochemistry (Moscow), vol. 71, no. 8, pp. 851-860, 2006.
132. C. Schiesling, N. Kieper, K. Seidel, and R. Krüger, "Review: Familial Parkinson's disease - genetics, clinical phenotype and neuropathology in relation to the common sporadic formof the disease," Neuropathology and Applied Neurobiology, vol. 34, no. 3, pp. 255-271, 2008.
133. H. Jiang, Y. Ren, E. Y. Yuen et al., "Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells," Nature Communications, vol. 3, article 668, 2012.
134. D. Kirik and A. Björklund, "Parkinson's disease: viral vector delivery of parkin generates model results in rats," Gene Therapy, vol. 12, no. 9, pp. 727-729, 2005.
135. H. Yang, X. Zhou, X. Liu et al., "Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin," Biochemical and Biophysical Research Communications, vol. 410, no. 1, pp. 114-120, 2011.
136. F. P. Manfredsson, C. Burger, L. F. Sullivan, N. Muzyczka, A. S. Lewin, and R. J. Mandel, "rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease," Experimental Neurology, vol. 207, no. 2, pp. 289-301, 2007.
137. J.-C. Paterna, A. Leng, E. Weber, J. Feldon, and H. Büeler, "DJ-1 and parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice," MolecularTherapy, vol. 15, no. 4, pp. 698-704, 2007.
138. M. Yamada, Y. Mizuno, and H. Mochizuki, "Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson's disease," Human GeneTherapy, vol. 16, no. 2, pp. 262-270, 2005.
139. R. L. Klein, R. D. Dayton, K. M. Henderson, and L. Petrucelli, "Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model," Neuroscience Letters, vol. 401, no. 1-2, pp. 130-135, 2006.
140. L. Vercammen, A. van der Perren, E. Vaudano et al., "Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease," Molecular Therapy, vol. 14, no. 5, pp. 716-723, 2006.
141. C. Lo Bianco, B. L. Schneider, M. Bauer et al., "Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 50, pp. 17510-17515, 2004.
142. R. Mechoulam and L. A. Parker, "The endocannabinoid system and the brain," Annual Review of Psychology, vol. 64, pp. 21-47, 2013.
143. M. van der Stelt and V. di Marzo, "Cannabinoid receptors and their role in neuroprotection," NeuroMolecular Medicine, vol. 7, no. 1-2, pp. 37-50, 2005.
144. J. Nader, C. Rapino, B. Gennequin et al., "Prior stimulation of the endocannabinoid system prevents methamphetamineinduced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors," Neuropharmacology, vol. 87, pp. 214-221, 2014.
145. L. Walter and N. Stella, "Cannabinoids and neuroinflammation," British Journal of Pharmacology, vol. 141, no. 5, pp. 775-785, 2004.
146. L. Walter, A. Franklin, A. Witting et al., "Nonpsychotropic cannabinoid receptors regulate microglial cell migration," The Journal of Neuroscience, vol. 23, no. 4, pp. 1398-1405, 2003.
147. J. Fernández-Ruiz, M. Moreno-Martet, C. Rodríguez-Cueto et al., "Prospects for cannabinoid therapies in basal ganglia disorders," British Journal of Pharmacology, vol. 163, no. 7, pp. 1365-1378, 2011.
148. D. A. Price, A. A. Martinez, A. Seillier et al., "WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinemouse model of Parkinson's disease," European Journal ofNeuroscience, vol. 29, no. 11, pp. 2177-2186, 2009.
149. Y. Sekine, Y. Ouchi, G. Sugihara et al., "Methamphetamine causes microglial activation in the brains of human abusers," Journal of Neuroscience, vol. 28, no. 22, pp. 5756-5761, 2008.
150. D. Wen, D. Sun, G. Zang et al., "Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats," Neuroscience, vol. 277, no. 6, pp. 14-25, 2014.
151. S. Yang, D. Wen, M. Dong et al., "Effects of cholecystokinin-8 on morphine-induced spatial referencememory impairment in mice," Behavioural Brain Research, vol. 256, pp. 346-353, 2013.
152. U. Zippel, A. Plagemann, and H. Davidowa, "Altered action of dopamine and cholecystokinin on lateral hypothalamic neurons in rats raised under different feeding conditions," Behavioural Brain Research, vol. 147, no. 1-2, pp. 89-94, 2003.
153. K. A. Helm, P. Rada, and B. G. Hoebel, "Cholecystokinin combined with serotonin in the hypothalamus limits accumbens dopamine release while increasing acetylcholine: a possible satiationmechanism," Brain Research, vol. 963, no. 1-2, pp. 290-297, 2003.
154. S. Li, Z. Ni, B. Cong et al., "CCK-8 inhibits LPS-induced IL-1β production in pulmonary interstitial macrophages by modulating PKA, p38, and NF-κB pathway," Shock, vol. 27, no. 6, pp. 678-686, 2007.
155. Q. Li, B. Cong, B. Shan et al., "Cholecystokinin octapeptide exerts its therapeutic effects on collagen-induced arthritis by suppressing both inflammatory and Th17 responses," Rheumatology International, vol. 31, no. 10, pp. 1291-1298, 2011.